Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00396175

Enrollment

355

Registered

2006-11-06

Start date

1998-03-31

Completion date

Unknown

Last updated

2022-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic Alopecia

Brief summary

A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.

Interventions

DRUGMK0906, finasteride / Duration of Treatment : 48 Weeks

DRUGComparator : placebo (unspecified) / Duration of Treatment : 48 Weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

40 Years to 60 Years

Healthy volunteers

Inclusion criteria

: * Men 40 to 60 years of age, and in good general physical and mental health, with androgenetic alopecia

Exclusion criteria

: * History of previous bladder surgery, acute urinary retention, urethral strictures, repeated urethral catheterizations, repeated urinary tract infections, or active urinary tract infections * History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any component of finasteride.

Design outcomes

Primary

Measure	Time frame
Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment	—

Secondary

Measure	Time frame
Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026